Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction During Transcatheter Aortic Valve Replacement: A Prospective IDE Trial (BASILICA)

Featured Lecture: Future Innovation in TAVR: Remaining Clinical Needs, Novel Technologies and Ancillary Device Strategies

TCT-19: Predicting TMVR-Related LVOT Obstruction: Concept of Fluid Mechanics Modeling

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

TCT-14: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve

Update of the NeoVas BRS Clinical Trials

New TAVR Devices: VitaFlow, Venus A Plus, and Venibri

The Endpoints for Aortic Valve Development

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!